ExonHit Secures Position in Splice Array Market With Affy Deal, Expands Agreement with BioMrieux | GenomeWeb

ExonHit Therapeutics this week further secured its place in the developing market for splice arrays with an agreement that will make its content available on Affymetrix's GeneChip platform, while broadening an existing agreement with French diagnostics firm BioMérieux.

Last month, ExonHit said that it would make its SpliceArrays — which contain alternative splicing content for specific gene families — available as a product on Agilent Technologies' microarray platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.